Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Joan Glusman"'
Publikováno v:
Cancer. 88:2047-2053
BACKGROUND An earlier trial of raloxifene, conducted in women with metastatic breast carcinoma who initially had responded to tamoxifen and subsequently developed disease progression, suggested no antitumor activity for raloxifene in tamoxifen-refrac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05fe6fb64524b9e0305edfd1fce97250
https://doi.org/10.1002/(sici)1097-0142(20000501)88:9<2047::aid-cncr10>3.0.co
https://doi.org/10.1002/(sici)1097-0142(20000501)88:9<2047::aid-cncr10>3.0.co
Autor:
Joan Glusman, Jose A. Camacho, Stephen A. Morris, Shira Rohde, John P. Bilezikian, Gexin Chen
Publikováno v:
Endocrinology. 132:261-268
Exposure of ROS 17/2.8 cells to dexamethasone (DEX) or retinoic acid (RA) increases and decreases, respectively, adenylate cyclase activity (ACA) in response to isoproterenol, forskolin, guanylylimidodiphosphate, or NaFl. Despite dramatic changes in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31f619523c70c98856ec73c53e009938
https://doi.org/10.1210/endo.132.1.8419127
https://doi.org/10.1210/endo.132.1.8419127
Publikováno v:
Endocrine Practice. 12:59
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2abc1548283356d4b44c489962a82b6
https://doi.org/10.1016/s1530-891x(20)44043-1
https://doi.org/10.1016/s1530-891x(20)44043-1